Table 1.
MSC products in COVID-19 treatment
| Product | Company | Source | Dose | Phase | Country | Trial ID NO | |
|---|---|---|---|---|---|---|---|
| 1 | VUM02 | VCANBIO | Allogenic UC-MSCs | 4E7 cells, i.v. at days 0, 3, and 6 | I II | China | NCT04252118 NCT04288102 |
| 2 | RYONCIL™(remestemcel-L) | Mesoblast, Ltd./Novartis | Allogenic BM-MSCs | 2E6 cells/kg, 2 times/week | III | USA | NCT04371393 |
| 3 | Multistem | Athersys, Inc | Allogenic BM-MSCs | – | II/III | USA | NCT04367077 |
| 4 | HB-adMSCs | Hope Biosciences | Autologous AT-MSCs | 5 times, i.v | II | USA | NCT04349631 |
| 5 | HB-adMSCs | Hope Biosciences | Allogenic AT-MSCs | 2E8 cells, i.v. at weeks 0, 2, 6, 10, and 14 | II | USA | NCT04348435 |
| 1E6 cells, at days 0, 3, 7, and 10 | II | USA | NCT04362189 | ||||
| 6 | PLX-PAD | Pluristem Ltd | Allogenic placenta MSCs | 3E8, i.v | II | USA, Germany, & Israel | NCT04389450 NCT04614025 |
| 7 | JadiCell™ | Therapeutic Solutions International | Allogenic UC-MSCs | (10 ± 2) E7 cells; at days 0 and 3 | I/II | USA | NCT04355728 |
| 8 | CYP-001 (Cymerus MSCs) | Cynata Therapeutics Ltd | iPSC-MSCs | 2E6 cells/kg, i.v | I/II | Australia | NCT04537351 |
| 9 | NestaCell | Cellavita | iPSC-MSCs | 2E7 cells i.v. at days 1, 3, 5, and 7 | II | Brazil | NCT04315987 |
| 10 | HCLM051 | Healios/Athersys, Inc | Allogenic BM-MSCs | 9E8 (± 20%) cells | II | Japan | NCT03807804 |
| 11 | itMSCs | Stemedica Cell Technologies, Inc | Allogenic BM-MSCs | – | II | USA | NCT04780685 |
| 12 | ACT-20 | Aspire Health Science | Allogenic UC-MSCs | 1E6 cells/kg, i.v | I/II | USA | NCT04398303 |
| 13 | i-MSC | Citius Pharma/Novellus | iPSC-MSCs | – | II | USA | – |
| 14 | CAStem | Zephyrm Biotech | ESC-MSCs | 3, 5 or 10 E6 cells/kg, i.v | I/II | China | NCT04331613 |
| 15 | ULSC-CV-01 | Restem, LLC | Allogenic UC-MSCs | 1E8 cells, i.v | I/IIa | USA | NCT04494386 |
| 16 | COVI-MSC | Sorrento Therapeutics, Inc | Allogeneic AT-MSCs | 1E6 cells/kg or 1.5E6 cells/kg, depending on CRP level | II | USA | NCT04728698 |
| 3E7 cells at days 0, 2, and 4 | II | USA | NCT04903327 NCT04905836 | ||||
| 1.85E7 cells at days 0, 2, and 4;3.7E7 cells at days 0, 2, and 4 | Ib | USA | NCT04909892 | ||||
| 17 | BX-U001 | Baylx Inc | Allogenic UC-MSCs | Low dose: 0.5E6 cells/kg; Middle dose: 1.0E6 cells/kg; High dose: 1.5E6 cells/kg | I/IIa | China | NCT04452097 |
| 18 | PSC-04 | Sorrento Therapeutics, Inc | Allogenic AT-MSCs | – | I | USA | NCT04486001 |
| 19 | BM-Allo.MSC | ImmunityBio, Inc./NantKwest | Allogenic BM-MSCs | – | Ib | USA | NCT04397796 |
| 20 | MB-MSC injection | IPM Biotech | Allogenic MB-MSCs | 9E7 cells, i.v. at days 1, 3, and 5 | I | China | ChiCTR2000029606 |
| 21 | LMSCs | Longeveron Inc | – | 1E8 cells, i.v. at days 0, 3, and 6 | I | USA | NCT04629105 |
| 22 | Descartes-30 | Cartesian Therapeutics | Allogenic UC-MSCs | – | I/II | USA | NCT04524962 |
| 23 | SB1-101 | Sentien Biotechnologies, Inc | Allogenic MB-MSCs with an FDA-approved plasmapheresis device | High dose: 7.5E8; Low dose: 2.5E8 | I/II | USA | NCT04445220 |
| 24 | AlloRx™ | Vitro Biopharma/GIOSTAR | Allogenic MSC engineered to secrete human DNases | – | I | USA | – |
| 25 | DW-MSC | Daewoong Pharmaceutical | Allogenic UC-MSCs | 5E7 cells, i.v | I | Indonesia | NCT04535856 |
| 26 | hDP-MSC injection | SH Bio-Tech | Allogenic DP-MSCs | 3E7 stem cells at days 1, 4, and 7 | I | China | NCT04336254 |
i.v., intravenous injection